BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25977332)

  • 21. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.
    Flak MB; Connell CM; Chelala C; Archibald K; Salako MA; Pirlo KJ; Lockley M; Wheatley SP; Balkwill FR; McNeish IA
    Mol Cancer; 2010 Jul; 9():175. PubMed ID: 20598155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Siurala M; Bramante S; Vassilev L; Hirvinen M; Parviainen S; Tähtinen S; Guse K; Cerullo V; Kanerva A; Kipar A; Vähä-Koskela M; Hemminki A
    Int J Cancer; 2015 Feb; 136(4):945-54. PubMed ID: 24975392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photoactivatable oncolytic adenovirus for optogenetic cancer therapy.
    Hagihara Y; Sakamoto A; Tokuda T; Yamashita T; Ikemoto S; Kimura A; Haruta M; Sasagawa K; Ohta J; Takayama K; Mizuguchi H
    Cell Death Dis; 2020 Jul; 11(7):570. PubMed ID: 32703933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
    Passaro C; Volpe M; Botta G; Scamardella E; Perruolo G; Gillespie D; Libertini S; Portella G
    Mol Oncol; 2015 Jan; 9(1):78-92. PubMed ID: 25139258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.
    Cerullo V; Diaconu I; Romano V; Hirvinen M; Ugolini M; Escutenaire S; Holm SL; Kipar A; Kanerva A; Hemminki A
    Mol Ther; 2012 Nov; 20(11):2076-86. PubMed ID: 22828500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
    Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
    Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
    Zhang L; Hedjran F; Larson C; Perez GL; Reid T
    Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
    Kanerva A; Raki M; Ranki T; Särkioja M; Koponen J; Desmond RA; Helin A; Stenman UH; Isoniemi H; Höckerstedt K; Ristimäki A; Hemminki A
    J Gene Med; 2007 Jan; 9(1):3-9. PubMed ID: 17149790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
    Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of natural killer cells in adenovirus-mediated p53 gene therapy.
    Carroll JL; Nielsen LL; Pruett SB; Mathis JM
    Mol Cancer Ther; 2001 Nov; 1(1):49-60. PubMed ID: 12467238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.